Workflow
γδ T cell immunotherapy
icon
Search documents
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
GlobeNewswire News Room· 2025-05-14 12:00
Core Insights - IN8bio, Inc. announced promising preclinical data for its INB-619 program, a γδ T cell therapy targeting CD-19, which effectively eliminated disease-causing B cells in patients with Systemic Lupus Erythematosus [1][2][3] Group 1: Treatment Potential - INB-619 shows potential as a novel treatment for autoimmune diseases by selectively clearing harmful B cells while minimizing inflammatory responses, unlike traditional T cell engagers [2][7] - The therapy demonstrated complete depletion of pathogenic B cells, including harmful IgG1 and IgM antibodies, indicating its effectiveness in treating autoimmune conditions [7][8] Group 2: Mechanism and Advantages - INB-619 expands and activates both Vδ1+ and Vδ2+ subtypes of γδ T cells, addressing the challenge of low γδ T cell levels in chronic disease patients [3][7] - The therapy does not trigger significant release of inflammatory cytokines, such as IL-6, which are commonly associated with severe side effects like cytokine release syndrome [8] Group 3: Future Directions - IN8bio is exploring potential partnerships and additional indications for autoimmune diseases and cancer where γδ T cell biology can be leveraged [4] - The company is advancing its lead program, INB-100, focused on acute myeloid leukemia, and evaluating other γδ T cell therapies for various oncology and autoimmune indications [5]